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Abstract
Background: Cefuroxime very rarely causes drug-induced liver injury. We present a case of a patient with
paradoxical worsening of jaundice caused by cefuroxime-induced cholestasis following therapeutic endoscopic
retrograde cholangiopancreatography for a distal common bile duct stone.
Case presentation: A 51-year-old, previously healthy Sri Lankan man presented to our hospital with obstructive
jaundice caused by a distal common bile duct stone. Endoscopic retrograde cholangiopancreatography with stone
extraction, common bile duct clearance, and stenting failed to improve the cholestasis, with paradoxical worsening
of his jaundice. A liver biopsy revealed features of drug-induced intrahepatic cholestasis. Although his case was
complicated by an episode of cholangitis, the patient made a complete recovery in 4 months with supportive
treatment and withdrawal of the offending drug.
Conclusions: This case highlights a very rare drug-induced liver injury caused by cefuroxime as well as our
approach to treating a patient with paradoxical worsening of jaundice after therapeutic endoscopic retrograde
cholangiopancreatography.
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Background
Cefuroxime is a second-generation cephalosporin known
to very rarely cause drug-induced liver injury (DILI).
There have been fewer than five previously reported
cases of cefuroxime causing DILI and cholestasis. In a
follow-up of a previous report of liver injury caused by
ampicillin, Köklü et al. [1] described a case of a 23-year-old
man who redeveloped liver injury 17 days after starting a
10-day course of oral cefuroxime (bilirubin 0.7 mg/dl,
alanine transaminase [ALT] 427 U/L, alkaline phosphatase
[ALP] 646 U/L), which resolved within 2 months, sug-
gesting cross-reactivity with ampicillin. In a report by
Chalasani et al. for the Drug-Induced Liver Injury
Network [2], among 300 cases of DILI in the United
States collected between 2004 and 2008, 5 cases were
attributed to cephalosporin, with single cases linked to
cefuroxime. In another report, Ekiz et al. described a
60-year-old woman who developed jaundice 4 days after a
10-day course of oral cefuroxime (bilirubin 17.9 mg/dl ris-
ing to 30 mg/dl, ALT 1527 U/L, ALP 1006 U/L), with pro-
gressive worsening of international normalized ratio (INR)
[1.9] and referral for transplant but with a subsequent full
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recovery [3]. Given the paucity of case reports of
cefuroxime-induced DILI, this drug belongs to category
D (one to four reported cases) according to a recently
suggested categorization of drugs implicated in hepato-
toxicity and DILI [4]. In this report, we present a case
of a patient with paradoxical worsening of jaundice due
to possible drug-induced cholestasis caused by cefuroxime
following therapeutic endoscopic retrograde cholangiopan-
creatography (ERCP) for distal common bile duct (CBD)
obstruction by a stone.
Case presentation
A previously healthy, 51-year-old Sri Lankan man pre-
sented with right upper quadrant colicky abdominal
pain of 3 days’ duration. The pain was associated with
yellow discoloration of the eyes, passage of dark urine,
and generalized itching. He had no significant past
medical, environmental, or social history. His clinical
examination revealed that he was afebrile but had
deep icterus, excoriations, and mild right upper quad-
rant abdominal tenderness. He had no stigmata of
chronic liver disease.
The results of laboratory investigations included a normal
full blood count and inflammatory markers, deranged liver
biochemistry (total bilirubin 6.4 mg/dl, ALP 325 IU/L,
aspartate transaminase [AST] 113 U/L, ALT 318 U/L),
normal liver function (serum albumin 3.8 g/dl, serum
globulin 2.6 g/dl, INR 1.00, activated partial thromboplastin
time [APTT] 29 seconds), and normal renal profile. An
ultrasound scan (USS) of the abdomen showed the pres-
ence of cholelithiasis with features of chronic cholecystitis
and a dilated CBD and intrahepatic ducts due to a distal
CBD obstruction. Contrast-enhanced computed tomog-
raphy of the abdomen confirmed the presence of a dis-
tal CBD stone causing proximal CBD and intrahepatic
duct dilation and cholelithiasis.
The patient underwent ERCP with sphincterotomy
and balloon extraction of a CBD stone 2 weeks from
the onset of symptoms. After surgery, the patient was
given intravenous cefuroxime 750 mg three times daily
for 1 day, followed by oral cefuroxime 500 mg twice
daily for 5 days. The patient’s symptoms and biochem-
istry failed to improve, with worsening of cholestasis
(total bilirubin 20.3 mg/dl, ALP 537 IU/L) following
the “successful” therapeutic ERCP. Repeat ERCP 1
week later showed a normal CBD with no residual
CBD stones. A 10-French, 10-cm CBD stent was
inserted at this stage.
The patient was then referred to a hepatologist for
evaluation of worsening jaundice post-ERCP. By this time,
the patient’s obstructive jaundice symptoms were severe
and disabling, and biochemical analysis revealed worsen-
ing cholestasis (total bilirubin 39 mg/dl, ALP 651 IU/L),
relatively normal liver enzymes (AST 61 U/L, ALT 62 U/L,
gamma-glutamyltransferase [GGT] 25 U/L] with normal
liver function (serum albumin 3.7 g/dl, serum globulin
1.9 g/dl, INR 1.00, APTT 29 seconds), normal full blood
count, normal inflammatory markers, and normal renal
profile. Repeat USS of the abdomen revealed multiple
cholelithiasis, chronic cholecystitis, stent in the CBD, and
no intrahepatic biliary radical dilation. Test results for the
patient’s hepatitis A immunoglobulin M (IgM), hepatitis E
antibodies, hepatitis B surface antigen, anti-hepatitis C
antibodies, and Leptospira IgM antibodies were negative.
On the basis of all the above-mentioned information,
an ultrasound-guided liver biopsy was performed. The
patient was commenced on prednisolone 40 mg daily,
ursodeoxycholic acid 300 mg three times daily, and cho-
lestyramine 5 g three times daily for symptomatic relief.
A liver biopsy showed no evidence of portal tract edema
or inflammation, lesions or paucity of bile ducts, bile in-
farcts or leaks, or inflammation or interphase hepatitis.
However, there was marked bilirubinostasis in zone 3
canaliculi, with surrounding hepatocytes revealing feathery
degeneration and surrounding inflammation (Fig. 1). These
features were compatible with intrahepatic cholestasis re-
lated to either drugs or sepsis.
One week later, the patient developed fever with chills
and rigors, worsening cholestasis clinically and biochem-
ically (total bilirubin 48 mg/dl, ALP 901 IU/L) with rela-
tively normal liver enzymes (AST 55 U/L, ALT 91 U/L,
GGT 43 U/L), raised inflammatory markers (C-reactive
protein 36 mg/dl), and neutrophil leukocytosis (white
blood cell count 14,400/mm3 with 80% neutrophils). A
clinical diagnosis of cholangitis was made, and the
patient was commenced on intravenous meropenem 1 g
three times daily, after blood cultures, for 14 days. The
CBD stent was removed endoscopically to exclude the
possibility of a blocked stent as the precipitant of
Fig. 1 Hepatic parenchyma around the central vein (lower left)
showing cholestasis, feathery degeneration, inflammation, and
lobular disarray (hematoxylin and stain, original magnification ×400)
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cholangitis. Oral prednisolone was tapered rapidly in
view of the infection. The cholangitis episode settled
with the antibiotics, with resolution of fever and normal-
izing of full blood count and inflammatory markers.
The patient’s cholestasis improved gradually over the
next 2 months with ursodeoxycholic acid therapy. He
had complete resolution of both clinical and biochemical
features (total bilirubin 1.1 mg/dl, ALP 135 IU/L) of
cholestasis 4 months into his illness. He was referred
back to a hepatobiliary surgeon for elective laparoscopic
cholecystectomy for residual cholelithiasis to prevent
recurrence of complications and was advised to avoid
cephalosporin use in the future. The timeline of the
patient’s clinical course is presented in Table 1.
Discussion
This case is unique and complicated, involving a very
rare DILI secondary to cefuroxime in the setting of
therapeutic ERCP for distal CBD obstruction. Previously
reported cases of DILI caused by cefuroxime were not
complicated by preexisting obstructive jaundice.
The cholestasis in our patent, which was due to distal
CBD obstruction by a stone, was expected to improve
following therapeutic ERCP. However, despite successful
stone extraction, CBD clearance, and stenting, our
patient’s cholestasis paradoxically continued to worsen.
Worsening cholestasis post-ERCP may be due to a
retained CBD stone, ascending cholangitis, a blocked or
migrated stent, or drug-induced cholestasis. In our patient,
the most likely reason was drug-induced cholestasis. This
was suggested by the absence of features of sepsis following
initial ERCP, the absence of ductal dilation seen on an USS
with stent in situ in the CBD, and the features present on
liver histology favoring intrahepatic cholestasis of drug-
induced etiology. The agents that may be responsible for
this may be the drugs used during or after ERCP. Our
patient was given propofol, pethidine during ERCP, and
cefuroxime post-ERCP. All of these agents are known
to cause cholestasis, but cefuroxime seems the likely
causative agent.
Cefuroxime is a second-generation cephalosporin very
rarely known to cause DILI. Prior to the present report,
fewer than five cases of cefuroxime causing DILI and
cholestasis had been reported [1–3]. Although the exact
mechanism of cholestatic DILI of cefuroxime is not known,
it is likely idiosyncratic in nature and due to hypersensitivity.
Conversely, a closely related third-generation cephalosporin,
ceftriaxone, is known to cause biliary sludge formation
because of the propensity of ceftriaxone to bind calcium
and form insoluble crystals in bile in the gallbladder,
resulting in biliary sludge or frank stones [5].
Our patient’s cholestasis worsened further following an
episode of cholangitis, which was successfully treated with
meropenem, thereby avoiding further exposure to ceph-
alosporin. Following successful treatment of his cholan-
gitis, the patient was managed with only ursodeoxycholic

















Initial presentation with right upper quadrant pain, jaundice, dark urine, and pruritus
Day 3 6.4 325 113 318 3.8 2.6 Normal <6
The patient underwent ERCP on day 14, followed by cefuroxime for 5 days.
Day 17 20.3 537 29 47 4.1 Normal <6
The patient underwent repeat ERCP on day 21 (1 week after the therapeutic ERCP), and a CBD stent was inserted.
He was then referred to a hepatologist for worsening obstructive jaundice.
Day 23 32.8 364 42 40 3.6 Normal <6
The patient was commenced on prednisolone 40 mg daily, ursodeoxycholic acid 300 mg, and cholestyramine 5 g
three times daily. The patient was readmitted with fever with rigors and worsening of jaundice on day 32.
Day 32 39 651 62 61 25 3.7 1.9
Stent removed endoscopically on day 33. The patient was treated for cholangitis with intravenous meropenem
for the next 14 days; prednisolone was tapered; ursodeoxycholic acid 300 mg and cholestyramine 5 g three times
daily were continued.
Day 34 35 595 57 52 18 3.23 1.57 Neutrophil leukocytosis (white blood cell
count 14,400/mm3 with 80% neutrophils)
42
Day 36 48 901 55 91 36
Day 40 38 752
4 months after
onset of illness
1.1 135 30 40
Abbreviations: ALP Alkaline phosphatase, ALT Alanine transaminase, AST Aspartate transaminase, CBD Common bile duct; ERCP Endoscopic retrograde
cholangiopancreatography GGT Gamma-glutamyltransaminase, FBC Full blood count, CRP C-reactive protein
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acid and cholestyramine. This resulted in gradual reso-
lution of his cholestasis, with complete resolution in 4
months.
The place of steroids in drug-induced cholestasis is
equivocal [6]. Corticosteroids can be effective for DILI
associated with autoimmune or systemic hypersensitivity
features. In our patient, there was no marked improvement
of cholestasis on commencing steroids. Furthermore, the
episode of cholangitis was worsened by steroids. Therefore,
steroids were tapered rapidly at the onset of cholangitis
with antibiotic cover.
Conclusions
Our patient’s case illustrates a rare DILI due to cefuroxime,
presenting as prolonged cholestatic jaundice following “suc-
cessful” therapeutic ERCP for an obstructing distal CBD
stone. Clinicians must be aware of the causes of worsening
cholestasis post-ERCP to manage as well as to prevent the
recurrence of similar complications in such patients.
Abbreviations
ALP: Alkaline phosphatase; ALT: Alanine transaminase; APTT: Activated partial
thromboplastin time; AST: Aspartate transaminase; CBD: Common bile duct;
CRP: C-reactive protein; DILI: Drug-induced liver injury; ERCP: Endoscopic
retrograde cholangiopancreatography; FBC: Full blood count; GGT: Gamma-
glutamyltransferase; IgM: Immunoglobulin M; INR: International normalized
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